Tempostatin (halofuginone) / Grunenthal, Akashi Therap - LARVOL DELTA

Properties of Beef Patties with Tenebrio molitor Powder as a Meat Replacer During Storage. (PubMed, Foods) - "Four treatments were prepared: Control (beef), HT50 (5% T. molitor powder), HT75 (7.5% T. molitor powder), and HT100 (10% T. molitor powder)...The presence of Bacillus cereus was attributed to T. molitor powder, as no growth was detected in the control. Among reformulated treatments, HT50 proved to be the most suitable beef patty formulation, as it maintained key physicochemical attributes such as color stability, texture, and oxidative stability, while providing nutritional benefits."

Journal

Evaluation of High-Temperature Sterilization Processes: Their Influence on the Mechanical Integrity of Additively Manufactured Polymeric Biomaterials. (PubMed, Materials (Basel)) - "This research examines how steam sterilization impacts the mechanical properties of four polymeric biomaterials frequently utilized in medical applications: MED610, PEEK, PET-G HT100, and RGD720...The results revealed that, while some materials exhibited significant alterations in mechanical properties, others demonstrated high resistance to thermal and humidity exposure during sterilization. These findings provide critical insights into the selection and optimization of polymeric biomaterials for sterilizable medical applications, ensuring their durability and safety in clinical use."

Journal

Reliability Evaluation of Temnography for Early Detection of Intracranial Lesions in Mild Traumatic Brain Injury Patient: A Preliminary Report of a New Portable, Non-Invasive Device. (PubMed, Open Access Emerg Med) - "This clinical investigation aims to assess the diagnostic accuracy of the TES HT100 medical device, utilizing electromagnetic fields for endocranial lesion screening...Moreover, another front of future development of this technology could be extending the study to include Territorial Emergency. In this context, Temnography could aid centralized decision-making in patient care."

Journal • Cardiovascular • CNS Disorders • Pediatrics • Vascular Neurology

Reliability Evaluation of Themnography for Early Detection of Intracranial Lesions in Mild Traumatic Brain Injury Patient: a preliminary report. (EUSEM 2024) - "This clinical investigation aims to assess the diagnostic accuracy of the TES HT100 medical device, utilizing electromagnetic fields for endocranial lesion screening...Territorial Emergency personnel will directly enrol head trauma patients from the field. This direct use of the device by emergency personnel, in addition to standard evaluation, holds promise for prognostic improvement and reduced treatment time, ensuring prompt referral to the most suitable facility."

Clinical • Cardiovascular • CNS Disorders • Hematological Disorders • Vascular Neurology

THE ESTIMATION OF PORTAL PRESSURE MODEL WITH NON-NEWTONIAN FLUID DYNAMICS IN LIVER CIRRHOSIS (AASLD 2024) - "The model was logη0_m=0.146TP+5.55(Ht/100)3-0.01Alb2-0.09... PVPG derived from non-Newtonian fluid dynamics may allow not only the screening of the progression of cirrhosis but also the determination and estimation of the treatment for portal hypertension."

Cardiovascular • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Liver Cirrhosis • Portal Hypertension

Effects Of Heat Therapy On Skeletal Muscle Interstitial Oxygenation And Mitochondrial Respiration In HFpEF Rats (ACSM 2024) - "No differences in MR for the SPI (S2, CON:7.5±0.7, HT:7.5±0.6; S3, CON:89.3±6.2, HT:90.8±5.5), SOL (S2, CON:14.5±2.2, HT:17.2±2.0; S3, CON:105.3±22.4, HT:111.9±8.5) or EDL (S2, CON:9.9±2.0, HT:10.7±1.2; S3, CON:128.0±13.6, HT:100.1±7.7) were observed between groups (p>0.05 for all)... HT enhanced skeletal muscle PO2is from rest to contractions partly via NO-mediated mechanisms. HT had no effects on skeletal muscle (SPI, SOL or EDL) S2 or S3 MR. These data support that chronic whole-body HT promotes beneficial adaptations within the oxygen transport pathway in a pre-clinical model of HFpEF."

Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Obesity

The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7. (PubMed, Cardiovasc Diabetol) - "Many agents targeting these genes, such as the ACC1/2 inhibitors GS-0976, PF-05221304, and MK-4074; the DGAT2 inhibitors IONIS-DGAT2Rx, PF-06427878, PF-0685571, and PF-07202954; the COL1A1 inhibitor HT-100; the stimulants Ga-CBP8 and RCT-01; the CPT1A inhibitors etomoxir, perhexiline, and teglicar; the FBP1 inhibitors CS-917 and MB07803; and the SMAD7 inhibitor mongersen, have been investigated in clinical trials...Many PCSK9 inhibitors, including alirocumab, evolocumab, inclisiran, AZD8233, Civi-007, MK-0616, and LIB003, have been investigated in clinical trials...Multiple materials can be used to deliver miR-26, but it is unclear which material is most suitable for mass production and clinical applications. This review focuses on the potential use of miR-26 in treating atherosclerosis to support the development of agents targeting it."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • ABCA1 • ACACA • ACSL3 • BMP2 • CD36 • COL1A1 • CPT1A • CTGF • EHHADH • HMGB1 • IFNA1 • IL1B • IL6 • MALT1 • RUNX2 • SCARB1 • SMAD7 • TCF7L2 • TNFA

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting. (PubMed, Front Immunol) - "Supernatants from hybridoma parent subclone 11B12B4 provided the highest positive PD-L1 signal, on Syrian hamster PBMCs and three cancer cell lines (HT100, HapT1 and HCPC1). Novel Syrian hamster anti-PD-L1 clone 11B12-1 induces tumour growth control in a hamster model of PDAC. Combining 11B12-1 with oncolytic adenovirus TILT-123 improves tumour growth control further and demonstrates good safety and toxicity profiles."

Journal • Oncolytic virus • Gastrointestinal Cancer • Immune Modulation • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • IL2 • TNFA

Ultrathin porous graphitic carbon nitride from recrystallized precursor toward significantly enhanced photocatalytic water splitting. (PubMed, J Colloid Interface Sci) - "Furthermore, Pt-NiCoO dual cocatalysts were employed on BCN-HT100 for achieving photocatalytic overall water splitting, and the AQY reached 4.9% at 405 nm. This work provides a meaningful reference to designing g-CN to achieve efficient solar energy conversion into hydrogen."

Journal

Effect of olive-derived antioxidants (3,4-dihydroxyphenylethanol and 3,4 dihydroxyphenylglycol) on sperm motility and fertility in liquid ram sperm stored at 15ºC or 5ºC. (PubMed, Reprod Domest Anim) - "However, in samples stored at 5°C, LIN (48, 72, 96 hr), STR (0 hr) and WOB (0, 48, 72, 96 hr) values significantly decreased in comparison with control treatment when high antioxidant concentrations were added (MIX100 or HT100)...According to the artificial insemination trial, no significant differences were observed when antioxidants were added. In conclusion, the use of HT and DHPG showed small impact in sperm motility and fertility was not affected (nor detrimentally nor positively) when insemination was carried out using antioxidant-supplemented liquid sperm."

Journal

Dietary curcumin supplementation effects on blood immunological profile and liver enzymatic activity of laying hens after exposure to high temperature conditions. (PubMed, J Therm Biol) - "Experimental groups contained two control groups (normal temperature control (NC) and heat stress control (HC) and 3 heat stress curcumin treatment groups (HT100, HT200 and HT300)...The available results also indicated that laying hens supplemented with curcumin under high temperature conditions had reduced H/L ratio, serum corticosterone levels, inflammatory cytokines response and liver enzymatic activity (ALT) which enhanced the immunity of laying hens under hot climatic conditions. Therefore, it is concluded that curcumin has ability to combat harsh environmental conditions which can be used as anti-inflammatory and immune booster feed additive in the poultry nutrition."

Journal

Effect of curcumin supplementation on TLR4 mediated non-specific immune responses in liver of laying hens under high-temperature conditions. (PubMed, J Therm Biol) - "Experimental groups contained two controls groups (high temperature and thermo-neutral control (HC and NC) fed basal diet) and three high-temperature curcumin treatments groups (HT100, HT200 and HT300)...Furthermore, PCNA, TLR4 and its downstream gene expression as well as protein expression (TLR4, NF-κB and PCNA) were significantly down regulated in heat stress curcumin supplemented group as compared to HC and NC group. Therefore, it is concluded that heat stressed hens supplemented with dietary curcumin enhance the immunity of laying hens and combat stressful environmental conditions."

Journal

Form 10-Q Processa Pharmaceuticals, Inc. (Processa Pharma Press Release) - "On August 29, 2019, we entered into an exclusive license agreement with Akashi Therapeutics, Inc. ('Akashi') to develop and commercialize an anti-fibrotic, anti-inflammatory drug, HT-100. As partial consideration for the licenses, we paid $10,000 to Akashi upon full execution of the license agreement...Once we have obtained adequate funding, we plan to develop HT-100 in rare adult fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis or Scleroderma. We may revisit potential pediatric indications, such as DMD, later."

Licensing / partnership

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02 (clinicaltrials.gov) - P2; N=10; Terminated; Sponsor: Akashi Therapeutics; Trial completion date: Apr 2017 ➔ Dec 2016; Trial primary completion date: Apr 2017 ➔ Dec 2016

Clinical • Trial completion date • Trial primary completion date

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy (clinicaltrials.gov) - P1b; N=17; Terminated; Sponsor: Akashi Therapeutics; Trial completion date: Apr 2017 ➔ Mar 2016; Trial primary completion date: Apr 2017 ➔ Mar 2016

Clinical • Trial completion date • Trial primary completion date

Open Label Extension Study of HT-100 in Patients With DMD (clinicaltrials.gov) - P2; N=17; Terminated; Sponsor: Akashi Therapeutics; Trial completion date: Apr 2017 ➔ Apr 2016; Trial primary completion date: Apr 2017 ➔ Apr 2016

Clinical • Trial completion date • Trial primary completion date